AMNEAL PHARMACEUTICALS, INC. Amortization of Intangible Assets
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Amortization of Intangible Assets of $34.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $34.90M, a 23.80% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $30.00M, a 33.63% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $35.70M, a 29.03% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $39.60M, a 8.55% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $166.30M, a 4.21% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $173.60M, a 6.37% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $163.20M, a 5.17% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $172.10M, a 0.35% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.90M 10-Q · filed 2026-08-06 | $64.90M 10-Q · filed 2026-08-06 | $100.60M derived: sum of 3 quarters · filed 2026-08-06 | $140.20M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $30.00M 10-Q · filed 2026-05-07 | $65.70M derived: sum of 2 quarters · filed 2026-05-07 | $105.30M derived: sum of 3 quarters · filed 2026-05-07 | $151.10M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $35.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $75.30M derived: sum of 2 quarters · filed 2026-02-27 | $121.10M derived: sum of 3 quarters · filed 2026-08-06 | $166.30M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $39.60M 10-Q · filed 2025-11-06 | $85.40M derived: sum of 2 quarters · filed 2026-08-06 | $130.60M 10-Q · filed 2025-11-06 | $180.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $45.80M 10-Q · filed 2026-08-06 | $91.00M 10-Q · filed 2026-08-06 | $141.30M derived: sum of 3 quarters · filed 2026-08-06 | $184.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $45.20M 10-Q · filed 2026-05-07 | $95.50M derived: sum of 2 quarters · filed 2026-05-07 | $138.80M derived: sum of 3 quarters · filed 2026-05-07 | $178.90M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $50.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $93.60M derived: sum of 2 quarters · filed 2026-02-27 | $133.70M derived: sum of 3 quarters · filed 2026-02-27 | $173.60M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $43.30M 10-Q · filed 2025-11-06 | $83.40M derived: sum of 2 quarters · filed 2025-11-06 | $123.30M 10-Q · filed 2025-11-06 | $164.00M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $40.10M 10-Q · filed 2025-08-07 | $80.00M 10-Q · filed 2025-08-07 | $120.70M derived: sum of 3 quarters · filed 2026-02-27 | $161.30M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $39.90M 10-Q · filed 2025-05-07 | $80.60M derived: sum of 2 quarters · filed 2026-02-27 | $121.20M derived: sum of 3 quarters · filed 2026-02-27 | $162.00M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $40.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $81.30M derived: sum of 2 quarters · filed 2026-02-27 | $122.10M derived: sum of 3 quarters · filed 2026-02-27 | $163.20M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $40.60M 10-Q · filed 2024-11-12 | $81.40M derived: sum of 2 quarters · filed 2024-11-12 | $122.50M 10-Q · filed 2024-11-12 | $167.20M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $40.80M 10-Q · filed 2024-08-09 | $81.90M 10-Q · filed 2024-08-09 | $126.60M derived: sum of 3 quarters · filed 2025-02-28 | $171.10M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $41.10M 10-Q · filed 2024-05-08 | $85.80M derived: sum of 2 quarters · filed 2025-02-28 | $130.30M derived: sum of 3 quarters · filed 2025-02-28 | $172.30M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $44.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $89.20M derived: sum of 2 quarters · filed 2025-02-28 | $131.20M derived: sum of 3 quarters · filed 2025-02-28 | $172.10M 10-K · filed 2025-02-28 | $172.06M 10-K · filed 2023-03-03 | |||
| 2022-09-30 | $44.50M 10-Q · filed 2023-11-09 | $44.55M 10-Q · filed 2022-11-07 | $86.50M derived: sum of 2 quarters · filed 2023-11-09 | $127.40M 10-Q · filed 2023-11-09 | $127.45M 10-Q · filed 2022-11-07 | $171.10M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $42.00M 10-Q · filed 2023-08-08 | $41.98M 10-Q · filed 2022-08-08 | $82.90M 10-Q · filed 2023-08-08 | $82.90M 10-Q · filed 2022-08-08 | $126.60M derived: sum of 3 quarters · filed 2024-03-14 | $170.41M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $40.90M 10-Q · filed 2023-05-09 | $40.92M 10-Q · filed 2022-05-06 | $84.60M derived: sum of 2 quarters · filed 2024-03-14 | $128.41M derived: sum of 3 quarters · filed 2024-03-14 | $171.93M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $43.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $87.51M derived: sum of 2 quarters · filed 2024-03-14 | $131.03M derived: sum of 3 quarters · filed 2024-03-14 | $172.70M 10-K · filed 2024-03-14 | $172.70M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $43.81M 10-Q · filed 2022-11-07 | $87.33M derived: sum of 2 quarters · filed 2022-11-07 | $129.00M 10-Q · filed 2022-11-07 | $172.87M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $43.52M 10-Q · filed 2022-08-08 | $85.19M 10-Q · filed 2022-08-08 | $129.06M derived: sum of 3 quarters · filed 2023-03-03 | $173.61M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $41.67M 10-Q · filed 2022-05-06 | $85.54M derived: sum of 2 quarters · filed 2023-03-03 | $130.09M derived: sum of 3 quarters · filed 2023-03-03 | $174.06M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $43.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $88.42M derived: sum of 2 quarters · filed 2023-03-03 | $132.39M derived: sum of 3 quarters · filed 2023-03-03 | $174.97M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $44.55M 10-Q · filed 2021-11-08 | $88.52M derived: sum of 2 quarters · filed 2021-11-08 | $131.10M 10-Q · filed 2021-11-08 | $171.28M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $43.98M 10-Q · filed 2021-08-09 | $86.55M 10-Q · filed 2021-08-09 | $126.73M derived: sum of 3 quarters · filed 2022-03-01 | $164.75M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $42.58M 10-Q · filed 2021-05-07 | $82.75M derived: sum of 2 quarters · filed 2022-03-01 | $120.77M derived: sum of 3 quarters · filed 2022-03-01 | $155.56M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $40.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $78.19M derived: sum of 2 quarters · filed 2022-03-01 | $112.99M derived: sum of 3 quarters · filed 2022-03-01 | $143.95M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $38.02M 10-Q · filed 2020-11-06 | $72.81M derived: sum of 2 quarters · filed 2020-11-06 | $103.77M 10-Q · filed 2020-11-06 | $203.62M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $34.80M 10-Q · filed 2020-08-06 | $65.76M 10-Q · filed 2020-08-06 | $165.60M derived: sum of 3 quarters · filed 2021-03-01 | $191.26M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $30.96M 10-Q · filed 2020-05-11 | $130.81M derived: sum of 2 quarters · filed 2021-03-01 | $156.46M derived: sum of 3 quarters · filed 2021-03-01 | $173.16M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $99.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $125.50M derived: sum of 2 quarters · filed 2021-03-01 | $142.19M derived: sum of 3 quarters · filed 2021-03-01 | $143.95M 10-K · filed 2021-03-01 | $72.99M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $25.66M 10-Q · filed 2019-11-07 | $42.35M derived: sum of 2 quarters · filed 2019-11-07 | $44.11M 10-Q · filed 2019-11-07 | $114.04M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-06-30 | $16.69M 10-Q · filed 2019-08-05 | $18.45M 10-Q · filed 2019-08-05 | $88.39M derived: sum of 3 quarters · filed 2021-03-01 | $89.67M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-03-31 | $1.76M 10-Q · filed 2019-05-09 | $71.69M derived: sum of 2 quarters · filed 2021-03-01 | $72.97M derived: sum of 3 quarters · filed 2021-03-01 | $73.86M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2017-12-31 | $69.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $71.21M derived: sum of 2 quarters · filed 2021-03-01 | $72.10M derived: sum of 3 quarters · filed 2021-03-01 | $72.99M 10-K · filed 2021-03-01 | $3.97M 10-K · filed 2019-03-01 | |||
| 2017-09-30 | $1.28M 10-Q · filed 2018-11-07 | $2.16M derived: sum of 2 quarters · filed 2018-11-07 | $3.05M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $886.00K 10-Q · filed 2018-08-09 | $1.77M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $3.70M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |